lifestyle.harcourthealth.com

Author: Sagimet Biosciences Inc.

Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer

April 20, 2026
Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

April 6, 2026
Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates

March 11, 2026
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences

February 25, 2026
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

February 10, 2026
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne

February 2, 2026